IL-22/IL-22R1 pathway enhances cholangiocarcinoma progression <i>via</i> ERK1/2 activation
The IL-22/IL-22R1 axis promotes CCA progression by activating ERK1/2 signaling. Targeting this pathway with ERK1/2 inhibitors offers potential therapeutic strategies for CCA.
Authors
- Jin Zhou (ORCID: https://orcid.org/0000-0002-0039-9758)
- Jing-Rui Chen
- Yi Bai (ORCID: https://orcid.org/0000-0002-1179-3734)
- Zhongmin Li (ORCID: https://orcid.org/0000-0002-0865-4864)
- Wen Tong
- Jinming Li (ORCID: https://orcid.org/0000-0003-0569-0824)
- Yamin Zhang (ORCID: https://orcid.org/0000-0001-7886-2901)
- Chao Wang (ORCID: https://orcid.org/0000-0001-5685-7626)
- Xuan Deng (ORCID: https://orcid.org/0000-0002-8528-6831)
- Sen Han (ORCID: https://orcid.org/0000-0003-2437-3322)
Institutions
- Tianjin Medical University (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.4251/wjgo.v17.i3.102083
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01